ENSC: חוב לטווח קצר להון עצמי Ensysce

The confirmed price history on the chart demonstrates the performance of Ensysce Biosciences (ENSC), where the metric value is 0.00. The business generates revenue by creating protected analgesics utilizing the TAAP system to eliminate overdoses. The specific nature of combating the opioid crisis makes the company resilient to macroeconomic fluctuations and inflation. The innovative method of drug activation in the gut provides a competitive advantage and protection against dumping.

For Ensysce Biosciences (ENSC), which operates within a protected US legal framework developing humanitarian analgesics, the current liabilities-to-equity ratio reflects the proportion of obligations due within one year relative to shareholders' equity, where low values confirm the absence of liquidity risks and sanction threats, allowing the investor to assess the balance between financial stability and business growth rates through short-term debt dynamics.